Acurx Pharmaceuticals
ACXP
18 hedge funds and large institutions have $185K invested in Acurx Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
3.59% less ownership
Funds ownership: 6.37% → 2.78% (-3.6%)
14% less funds holding
Funds holding: 21 → 18 (-3)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
72% less capital invested
Capital invested by funds: $674K → $185K (-$489K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.56K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.31K |
| 3 |
Morgan Stanley
New York
|
+$2.08K |
| 4 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$48 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$81K |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$74K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$13.1K |
| 4 |
MCA
McGuire Capital Advisors
Bethany,
Oklahoma
|
-$3.71K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$312 |
ACXP Hedge Fund Activity: Q2 2026 in Review
18 of the 8,345 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q2 2026, worth a combined $185K — down 72% from $674K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ACXP and 1 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $3.56K. The largest seller was Jane Street, cutting an estimated $81K.
- 18 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q2 2026, down from 21 in Q1 2026.
- Funds reported $185K of Acurx Pharmaceuticals stock for Q2 2026, down 72% quarter-over-quarter.
- 1 fund opened new Acurx Pharmaceuticals positions in Q2 2026 and 4 closed out, a net change of -3 holders.
- The largest Acurx Pharmaceuticals buyer in Q2 2026 was Tower Research Capital (TRC), an estimated $3.56K added.
- The largest Acurx Pharmaceuticals seller in Q2 2026 was Jane Street, an estimated $81K sold.
Based on aggregated 13F filings for Q2 2026.